Parameter | Study | |||
---|---|---|---|---|
Trial 1 | Trial 2 | Trial 3 | ||
DP | ASÂ +Â SP | ASÂ +Â SP | ASÂ +Â SP | |
Year | 2007–2010 | 2007–2010 | 2010–2011 | 2012–2014 |
No. of patients | 59 | 61 | 100 | 83 |
Location (%) | ||||
 Jalalabad | 41 (69) | 42 (69) | 100 (100) | – |
 Takhar | 6 (10) | 5 (8) | – | – |
 Faryab | 1 (2) | 3 (5) | – | – |
 Kunar | 11 (19) | 11 (18) | – | 83 (100) |
Age (years) (median, range) | 11 (2–52) | 13 (1–70) | 15.5 (3–55) | 18 (1–74) |
Gender male/female (ratio) | 43/16 (2.7) | 35/26 (1.3) | 60/40 (1.5) | 49/34 (1.4) |
Body weight (kg) (median, range) | 31 (8–87) | 35 (7.5-85) | 50 (10-72) | 49 (10–75) |
Median parasitaemia/µl (range) | 6760 (1220–90,000) | 7200 (900–62,160) | 4680 (1000–95,000) | 3220 (500–59,520) |
No. of patients with gametocytes (%) | 13 (22) | 29 (48) | 19 (19) | 42 (51) |
Mean axillary temp (°C) ± SD | 37.9 ± 1.1 | 37.9 ± 1.0 | 38.4 ± 0.8 | 38.4 ± 0.9 |
Mean hemoglobin (g/dl) ± SD | 11.2 ± 1.3 | 11.2 ± 1.4 | 11.50 ± 0.9 | 11.6 ± 1.9 |
Mean total drug dose (mg/kg) ± SD | ||||
 Artemisinin derivative | 6.7 ± 1.2 (DHA) | 10.42 ± 1.9 (AS) | 10.5 ± 2.0 (AS) | 10.5 ± 2.4 (AS) |
 Partner drug | 53.9 ± 9.3 (PIP) | 27.35 ± 11.9 (SUL) | 26.8 ± 5.0 (SUL) | 27.3 ± 6.1 (SUL) |